Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Feb 16;10(4):e019889.
doi: 10.1161/JAHA.120.019889. Epub 2021 Feb 9.

Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction: Bleeding Avoidance First and Foremost

Davide Cao  1 , George Dangas  1 , Roxana Mehran  1
Affiliations
Editorial

Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction: Bleeding Avoidance First and Foremost

Davide Cao et al. J Am Heart Assoc. .
No abstract available

Keywords: Editorials; aspirin; bleeding; coronary artery disease; myocardial infarction; thrombosis; ticagrelor.

PubMed Disclaimer

Conflict of interest statement

Dr Mehran reports grants from Abbott Laboratories, AstraZeneca, Bayer, Beth Israel Deaconess, Bristol Myers Squibb, CSL Behring, DSI, Medtronic, Novartis Pharmaceuticals, and OrbusNeich; personal fees from Abbott Laboratories, Boston Scientific, Medscape/WebMD, Siemens Medical Solutions, PLx Opco Inc/dba PLx Pharma Inc, Roivant Sciences, Sanofi, Medtelligence (Janssen Scientific Affairs), and Janssen Scientific Affairs; other from Abbott Laboratories, Abiomed, Bristol Myers Squibb, Claret Medical, Elixir Medical, The Medicines Company, Spectranetics/Philips/Volcano Corp, and Watermark Research Partners; and nonfinancial support and other from Regeneron Pharmaceuticals and Idorsia Pharmaceuticals Ltd. Dr Dangas reports consulting fees or honoraria from AstraZeneca, Biosensors, Boston Scientific, and Medtronic; reports research grants to the institution from Biotronik and Abbott Laboratories; and has equity (entirely divested) with Medtronic. Dr Cao has no disclosures to report.

Comment on

References

    1. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057. DOI: 10.1056/NEJMoa0904327. - DOI - PubMed
    1. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, et al. Long‐term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–1800. DOI: 10.1056/NEJMoa1500857. - DOI - PubMed
    1. Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383:207–217. DOI: 10.1056/NEJMoa1916870. - DOI - PubMed
    1. Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstråle W, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019;381:1309–1320. DOI: 10.1056/NEJMoa1908077. - DOI - PubMed
    1. Yeh RW, Secemsky EA, Kereiakes DJ, Normand S‐L, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735–1749. DOI: 10.1001/jama.2016.3775. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources